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EDITORAL
A RARE GLIMPSE AT THE EFFICACY OF PRIMAQUINE
J. KEVIN BAIRD
ALERTAsia Foundation, Jakarta, Indonesia
Primaquine, the only tool in our drug toolbox for prevent-
ing relapse of Plasmodium vivax or P. ovale malaria, may be
the most enigmatic of the most commonly prescribed drugs
today. Despite more than 50 years of continuous use by mil-
lions of people each year, we do not understand how it works.
Its complex metabolism generates a dozen known metabo-
lites, and none of these has been definitively linked either to
its potent activity against hypnozoites or to its hemolytic tox-
icity to people having an inborn deficiency of glucose-6-
phosphate dehydrogenase.
The drug is a poster child for neglect of basic and applied
research bearing directly upon one of the most prevalent
parasitic infections of the tropics.1 How many common infec-
tions in the developed world have only a single therapy avail-
able, and one that has been around for more than 50 years?
How many of those therapies have unknown mechanisms of
activity? Even worse, is there any therapy prescribed against
developed world infections that we do not know if the drug is
actually working?
The current efficacy of primaquine against relapses by P.
vivax malaria, proven more than 50 years ago in clinical
trials, is almost completely unknown. The evaluation of
the therapeutic efficacy of primaquine against relapse has
long been in the “too hard to do box.” And it is hard. Plas-
modium vivax malaria presents daunting confounders, as
well as logistical and ethical obstacles against evaluating
drugs preventing relapse. Molecular markers to distinguish
relapse from either reinfection or recrudescence provide only
ambiguities. Chloroquine as a companion blood schizonticide
may not be relied upon to clear the bloodstream of parasites
where resistance to it occurs, and its lingering blood levels
may effectively clear chloroquine-sensitive parasites emerg-
ing from primaquine-resistant relapses. Finally, a series of
early clinical trials suggested primaquine might require chlo-
roquine or quinine to achieve its potent killing of formed
hypnozoites.2
There is no validated procedure for demonstrating resis-
tance to primaquine, but it would look something like this:
primaquine administered with quinine under direct supervi-
sion of subjects who must be followed for at least 60 days in
areas where reinfection is highly unlikely. Moreover, the
natural relapse rate for the area would have to be known
beforehand, or, ideally, evaluated in randomized fashion in
people receiving only quinine therapy.3 This approach, in my
hands, consistently failed to clear ethical committees in Indo-
nesia and the work was never done. Another approach, ex-
perimental challenge of human subjects, faces perhaps less
daunting ethical challenges but imposes relatively huge
costs.
Epidemiology offers another approach to examining the
efficacy of primaquine. Twelve years ago in the American
Journal of Tropical Medicine and Hygiene, Jelinek and oth-
ers4 published a study of primaquine therapy among Euro-
pean travelers with P. vivax malaria. Their data showed a
12-fold higher risk of relapse after standard primaquine
therapy among travelers who acquired their infections in
New Guinea, and thus offered perhaps the first external vali-
dation of the notion that the primaquine-tolerant Chesson
strain of P. vivax from New Guinea (isolated in 1944) may
actually be representative of strains occurring on that island
today.
In this issue of the journal, Goller and others5 report the
results of a meta-analysis of 11 randomized clinical trials and
9 observational studies of primaquine therapy against relapse
by P. vivax conducted over the past 17 years. They divided the
studies geographically and demonstrate substantially higher
risk of primaquine failure in Thailand compared with India or
Brazil, but in any location the efficacy of standard primaquine
therapy (total adult dose 210 mg base) was approximately
80%. This finding offers perhaps the most substantial justifi-
cation of the recent recommendation by the U.S. Centers for
Disease Control and Prevention to adopt a total adult dose of
420 mg base as standard therapy against relapse.6 Moreover,
their findings also offer substantiation of the sentiment
among practitioners that the commonly prescribed total
adult dose of primaquine (whether 210 or 420 mg) may be
inadequate for people who weigh substantially more than
60 kg.7 Their findings offer a sound basis for the recent rec-
ommendation to administer a total dose of 6 mg/kg (30 mg
base/day) for as long as the patient’s weight dictates dosing.8
This analysis, although not free of potential confounding fac-
tors, provides an all too rare glimpse at the performance of
the only drug we have for preventing relapse of P. vivax
malaria.
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